Healthcare spending for the privately insured increased 3.4% in 2014 despite a decline in the use of healthcare services.
Healthcare spending for the privately insured increased 3.4% in 2014 despite a decline in the use of healthcare services, according to a report from the Health Care Cost Institute (HCCI).
The 2014 Health Care Cost and Utilization Report analyzes healthcare spending trends for Americans young than the age of 65 years and covered by employer-sponsored insurance from 2010 to 2014. Over the 5-year period per capita spending growth grew between 3% and 4% each year.
The report found that spending on brand prescription drugs increased by $45 per capita in 2014 despite a 16% decrease in the use of these drugs. The report attributes the increase in spending to the use of the hepatitis C drugs Olysio, Sovaldi, and Havoni.
“It’s striking to see the impact high priced drugs can have on health care spending, particularly in the case of three hepatitis C drugs, where use is relatively low,” HCCI Senior Researcher Amanda Frost, said in a statement. “With more high-priced drugs set to enter the market, higher spending on brand prescriptions is a potential trend to watch.”
In 2014, the largest decline in healthcare service utilization was for acute admissions (-2.7%) and the largest average price increase was for acute inpatient admissions, which increased $831 per admission (4.6%).
HCCI found that women spend more out of pocket each year, with the difference between what men and women spend reaching $237 in 2014, and the gap between the young and the old increased. In 2010, the difference between the oldest and youngest age groups was $6281, which increased to $6806 in 2014.
“We’re pleased to release our fifth annual health care spending report,” said HCCI Executive Director David Newman. “With the implementation of the Affordable Care Act, HCCI looks forward over the coming years to continue its analysis of health care trends, tracking any changes brought by the ACA in order to aid and improve the U.S. health care system.”
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
March 21st 2025Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen